Angiodynamic Inc (ANGO) Beta Value: Understanding the Market Risk

The 36-month beta value for ANGO is also noteworthy at 0.67. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”

The public float for ANGO is 38.57M, and at present, short sellers hold a 6.37% of that float. The average trading volume of ANGO on April 04, 2024 was 517.35K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

ANGO) stock’s latest price update

Angiodynamic Inc (NASDAQ: ANGO) has seen a rise in its stock price by 12.34 in relation to its previous close of 6.08. However, the company has experienced a 19.82% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-02 that AngioDynamics (ANGO) announces its settlement agreement with BD’s affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.

ANGO’s Market Performance

Angiodynamic Inc (ANGO) has seen a 19.82% rise in stock performance for the week, with a 21.53% gain in the past month and a -11.64% plunge in the past quarter. The volatility ratio for the week is 4.77%, and the volatility levels for the past 30 days are at 4.26% for ANGO. The simple moving average for the past 20 days is 21.92% for ANGO’s stock, with a -5.77% simple moving average for the past 200 days.

Analysts’ Opinion of ANGO

Many brokerage firms have already submitted their reports for ANGO stocks, with H.C. Wainwright repeating the rating for ANGO by listing it as a “Buy.” The predicted price for ANGO in the upcoming period, according to H.C. Wainwright is $19 based on the research report published on September 25, 2023 of the previous year 2023.

Raymond James, on the other hand, stated in their research note that they expect to see ANGO reach a price target of $13, previously predicting the price at $14. The rating they have provided for ANGO stocks is “Outperform” according to the report published on April 17th, 2023.

Canaccord Genuity gave a rating of “Buy” to ANGO, setting the target price at $37 in the report published on October 15th of the previous year.

ANGO Trading at 17.62% from the 50-Day Moving Average

After a stumble in the market that brought ANGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.98% of loss for the given period.

Volatility was left at 4.26%, however, over the last 30 days, the volatility rate increased by 4.77%, as shares surge +22.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.02% upper at present.

During the last 5 trading sessions, ANGO rose by +19.82%, which changed the moving average for the period of 200-days by -38.36% in comparison to the 20-day moving average, which settled at $5.66. In addition, Angiodynamic Inc saw -12.88% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for ANGO

Current profitability levels for the company are sitting at:

  • 0.04 for the present operating margin
  • 0.51 for the gross margin

The net margin for Angiodynamic Inc stands at -0.04. The total capital return value is set at 0.03. Equity return is now at value -3.49, with -2.67 for asset returns.

Based on Angiodynamic Inc (ANGO), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -2.0. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 6.12.

Currently, EBITDA for the company is 11.64 million with net debt to EBITDA at 1.67. When we switch over and look at the enterprise to sales, we see a ratio of 0.65. The receivables turnover for the company is 6.39for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.38.


In summary, Angiodynamic Inc (ANGO) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts